13 Papers
30 Citations
Jing Wang is an academic researcher from Tianjin Medical University General Hospital. The author has contributed to research in topics: Lung cancer & Osimertinib. The author has an hindex of 4, co-authored 10 publications.
Chat about Author
Papers
CDK4/6 inhibitor palbociclib overcomes acquired resistance to third-generation EGFR inhibitor osimertinib in non-small cell lung cancer (NSCLC).
TL;DR: The third‐generation EGFR‐TKI, represented by osimertinib, has been widely used in clinical practice; however, resistance eventually emerges and it remains unclear whether an abnormal cell cycle is involved in acquired resistance, and whether the combination of palbociclib (CDK4/6 inhibitor) and osimerinib can overcome the third-generation TKI resistance.
37
LKB1 gene inactivation does not sensitize non-small cell lung cancer cells to mTOR inhibitors in vitro.
TL;DR: LKB1 gene inactivation in NSCLC cells does not increase the sensitivity to the mTOR inhibitors, and the negative feedback activation of AKT by mTOR inhibition may contribute to the resistance of NSCLc cells to m TOR inhibitors.
Survey and analysis of awareness of lung cancer prevention and control in a LDCT lung cancer screening project in Tianjin Dagang Oilfield of China
Guanhua Ren,Jianfei Ye,Yaguang Fan,Jing Wang,Zhijuan Sun,Hui Jia,Xinxin Du,Chaohua Hou,Ying Wang,Yongcheng Zhao,Qinghua Zhou +10 more
TL;DR: Education level and smoking affect the awareness of lung cancer prevention and control, health education for lung cancer should be conducted especially in population with low education level.
8
Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 study
Linlin Zhang,Liuchun Wang,Jingya Wang,Jinliang Chen,Zhaoting Meng,Zhujun Liu,Xiangli Jiang,Xinyue Wang,Chun-Nung Huang,Peng Chen,Yan Liang,Richeng Jiang,Jing Wang,Diansheng Zhong,Yanhong Shang,Yan Zhang,Cuiying Zhang,Dingzhi Huang +17 more
TL;DR: Anlotinib combined with icotinib was effective and well-tolerated as a first-line treatment option for EGFR mutation-positive advanced NSCLC with or without concurrent mutations.
8
[Value of Immunohistochemical Methods in Detecting EML4-ALK Fusion Mutations: A Meta-analysis].
TL;DR: IHC can be a simple and rapid way in screening EML4-ALK fusion gene mutation and exhibits important clinical values as well as evaluating the accuracy and clinical value of this method.
7